Back to News
Market Impact: 0.3
Compass Pathways Q3 Earnings Call Highlights
Source: marketbeat.com
Healthcare & BiotechRegulation & LegislationProduct LaunchesCorporate Guidance & Outlook
Compass Pathways expects to complete its rolling New Drug Application submission for COMP360, an investigational psilocybin treatment for treatment-resistant depression, within two weeks. The company is preparing for a potential U.S. launch in the first half of 2027; the treatment remains investigational.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
CMPS0.65
More News
- Stifel reiterates Compass Pathways stock rating on NDA progress
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- 5 things to watch on Election Day as Democrats push for control of Congress
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- ‘Lawyer up’: Democrats take the House, and warn Trump’s family businesses are first in line for subpoenas
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge